Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK.
Lau DK, Luk IY, Jenkins LJ, Martin A, Williams DS, Schoffer KL, Chionh F, Buchert M, Sjoquist K, Boussioutas A, Hayes SA, Ernst M, Weickhardt AJ, Pavlakis N, Tebbutt NC, Mariadason JM. Lau DK, et al. Among authors: sjoquist k. Mol Cancer Ther. 2021 Apr;20(4):704-715. doi: 10.1158/1535-7163.MCT-20-0836. Epub 2021 Feb 9. Mol Cancer Ther. 2021. PMID: 33563752 Clinical Trial.
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
Tebbutt NC, Price TJ, Ferraro DA, Wong N, Veillard AS, Hall M, Sjoquist KM, Pavlakis N, Strickland A, Varma SC, Cooray P, Young R, Underhill C, Shannon JA, Ganju V, Gebski V. Tebbutt NC, et al. Br J Cancer. 2016 Mar 1;114(5):505-9. doi: 10.1038/bjc.2015.440. Epub 2016 Feb 11. Br J Cancer. 2016. PMID: 26867157 Free PMC article. Clinical Trial.
Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.
Pavlakis N, Sjoquist KM, Martin AJ, Tsobanis E, Yip S, Kang YK, Bang YJ, Alcindor T, O'Callaghan CJ, Burnell MJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Wong M, Strickland A, Kim JW, Zalcberg JR, Simes J, Goldstein D. Pavlakis N, et al. J Clin Oncol. 2016 Aug 10;34(23):2728-35. doi: 10.1200/JCO.2015.65.1901. Epub 2016 Jun 20. J Clin Oncol. 2016. PMID: 27325864 Free PMC article. Clinical Trial.
TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer.
Ferraro D, Goldstein D, O'Connell RL, Zalcberg JR, Sjoquist KM, Tebbutt NC, Grimison P, McLachlan S, Lipton LL, Vasey P, Gebski VJ, Aiken C, Cronk M, Ng S, Karapetis CS, Shannon J; behalf of the the Australasian Gastro-Intestinal Trials Group. Ferraro D, et al. Among authors: sjoquist km. Cancer Chemother Pharmacol. 2016 Aug;78(2):361-7. doi: 10.1007/s00280-016-3089-4. Epub 2016 Jun 22. Cancer Chemother Pharmacol. 2016. PMID: 27335026 Clinical Trial.
Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma.
Martin AJ, Gibbs E, Sjoquist K, Pavlakis N, Simes J, Price T, Shannon J, Gill S, Jain V, Liu G, Kannourakis G, Kim YH, Kim JW, Goldstein D; INTEGRATE I investigators. Martin AJ, et al. Among authors: sjoquist k. Gastric Cancer. 2018 May;21(3):473-480. doi: 10.1007/s10120-017-0754-1. Epub 2017 Aug 16. Gastric Cancer. 2018. PMID: 28815316 Clinical Trial.
Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project.
Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Falcone A, Porschen R, Fuchs C, Diaz-Rubio E, Aranda E, Bokemeyer C, Souglakos I, Kabbinavar FF, Chibaudel B, Meyers JP, Sargent DJ, de Gramont A, Zalcberg JR; Fondation Aide et Recherche en Cancerologie Digestive Group (ARCAD). Sjoquist KM, et al. J Natl Cancer Inst. 2018 Jun 1;110(6):638-648. doi: 10.1093/jnci/djx253. J Natl Cancer Inst. 2018. PMID: 29267900 Free PMC article. Clinical Trial.
Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in Advanced Gastric Cancer.
Vasista A, Stockler M, Martin A, Pavlakis N, Sjoquist K, Goldstein D, Gill S, Jain V, Liu G, Kannourakis G, Kim YH, Nott L, Snow S, Burge M, Harris D, Jonker D, Chua YJ, Epstein R, Bonaventura A, Kiely B. Vasista A, et al. Among authors: sjoquist k. Oncologist. 2019 Nov;24(11):e1102-e1107. doi: 10.1634/theoncologist.2018-0613. Epub 2019 Apr 1. Oncologist. 2019. PMID: 30936377 Free PMC article. Clinical Trial.
Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group.
Dunn C, Hong W, Gibbs P, Ackland S, Sjoquist K, Tebbutt NC, Price T, Burge M. Dunn C, et al. Among authors: sjoquist k. Clin Colorectal Cancer. 2021 Sep;20(3):245-255. doi: 10.1016/j.clcc.2021.05.001. Epub 2021 May 11. Clin Colorectal Cancer. 2021. PMID: 34103264
53 results